Skip to main content



22-10-2019 | Oncology | News | Article

Life-gained selection approach could expand benefits of lung cancer screening

Using a life–years gained approach to select patients for lung cancer screening could maximize its benefits for current and ex-smokers who have both a high risk for lung cancer and a long life expectancy, US research suggests.

21-10-2019 | Oncology | News | Article

Treatment-free survival proposed as novel RCC immunotherapy endpoint

Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.

15-10-2019 | Oncology | News | Article

Value of blood-based screening for ALK fusions shown in patients with NSCLC

Blood-based next-generation sequencing can be used to identify patients with non-small-cell lung cancer and ALK fusions who will benefit from treatment with alectinib, show results of the phase II/III blood-first assay screening trial.

14-10-2019 | Oncology | News | Article

Olaparib–temozolomide combination has ‘substantial’ activity in relapsed SCLC

A phase I/II trial has shown promising efficacy and tolerability for the combination of the PARP inhibitor olaparib with temozolomide in patients with previously treated small-cell lung cancer.

11-10-2019 | Oncology | News | Article

IMpower110: OS boost with first-line atezolizumab in PD-L1-high metastatic NSCLC

An interim analysis of the IMpower110 study has demonstrated an overall survival improvement with atezolizumab versus chemotherapy in treatment-naïve patients with stage IV non-small-cell lung cancer and high levels of PD-L1 expression.

10-10-2019 | Oncology | News | Article

​​​​​​​Nivolumab–ipilimumab an option for untreated, advanced NSCLC regardless of PD-L1 levels

Individuals with advanced non-small-cell lung cancer derive an overall survival benefit from first-line treatment with nivolumab plus ipilimumab irrespective of PD-L1 expression, report the CheckMate 227 investigators.

09-10-2019 | Oncology | News | Article

No survival improvement with pembrolizumab in malignant pleural mesothelioma

Pembrolizumab does not confer a progression free survival or overall survival advantage in previously treated patients with advanced malignant pleural mesothelioma, suggest findings from the PROMISE-meso trial.

04-10-2019 | Oncology | News | Article

Metformin prolongs PFS in patients with EGFR-mutated lung adenocarcinoma

Research published in JAMA Oncology shows that patients with EGFR-mutated lung adenocarcinoma have prolonged progression free survival when tyrosine kinase inhibitor treatment is supplemented with metformin.

03-10-2019 | Oncology | News | Article

CASPIAN: Adding durvalumab to chemotherapy improves SCLC PROs

The combination of durvalumab plus chemotherapy is associated with better patient-reported outcomes than chemotherapy alone, suggests data from the CASPIAN trial comprising treatment-naïve individuals with extensive-stage small-cell lung cancer.

29-09-2019 | Oncology | News | Article

FLAURA shows OS boost with osimertinib in advanced NSCLC

The FLAURA trial comparing osimertinib with erlotinib or gefitinib in the first-line treatment of EGFR-mutated, advanced non-small-cell lung cancer has shown positive overall survival results favoring the third-generation EGFR–tyrosine kinase inhibitor.

18-09-2019 | Oncology | News | Article

Nivolumab confers NSCLC survival advantage over 5 years

Individuals with advanced non-small-cell lung cancer continue to derive a long-term survival benefit from second- or later-line treatment with nivolumab versus docetaxel, according to 5-year results from the CheckMate 017 and 057 trials.

18-09-2019 | Oncology | News | Article

Trilaciclib shows myelopreservation benefits in patients with SCLC

Trilaciclib affords myelopreservation in individuals with small-cell lung cancer treated with first-line chemotherapy, without impacting treatment efficacy, research indicates.

16-09-2019 | Oncology | News | Article

Special NSCLC populations can benefit from nivolumab plus ipilimumab

Non-small-cell lung cancer patients with poor performance status or comorbidity experience a similar adverse event rate to those with normal performance status when treated with nivolumab plus ipilimumab, say researchers.

13-09-2019 | Oncology | News | Article

IMpower131: Strongly PD-L1-positive NSCLC patients may benefit from atezolizumab–chemotherapy

The final analysis of the IMpower131 trial reveals an overall survival benefit with the addition of atezolizumab to carboplatin and nab-paclitaxel chemotherapy for treatment-naïve patients with stage IV squamous non-small-cell lung cancer who strongly express PD-L1.

12-09-2019 | Oncology | News | Article

LIBRETTO-001: Selpercatinib achieves high ORRs in RET fusion-positive NSCLC

Selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced non-small-cell lung cancer harboring RET fusions, show updated trial data presented at the IASLC World Conference on Lung Cancer 2019.

12-09-2019 | Oncology | News | Article

microRNA plus LDCT guides optimal lung cancer screening intensity

Combining low-dose computed tomography with a blood microRNA test can help establish the most appropriate screening frequency among heavy smokers at risk for lung cancer, study data show.

11-09-2019 | Oncology | News | Article

VATS in-hospital outcomes may better those of open lobectomy

Video-assisted thoracic surgery lobectomy is associated with less pain, fewer in-hospital complications, and shorter hospital stays compared with open lobectomy for early-stage lung cancer, data from the VIOLET study indicate.

10-09-2019 | Oncology | News | Article

Durable pembrolizumab survival benefit seen in KEYNOTE-024

Three-year results from the KEYNOTE-024 trial point to the durable efficacy of pembrolizumab monotherapy when used for the first-line treatment of metastatic non-small-cell lung cancer.

09-09-2019 | Non-small-cell lung cancer | News | Article

TMB does not predict NSCLC pembrolizumab–chemotherapy response

Exploratory analyses from two KEYNOTE trials reported at the IASLC World Conference on Lung Cancer 2019 in Barcelona, Spain, rule out a significant correlation between tumor mutational burden and survival of patients with non-small-cell lung cancer who are treated with pembrolizumab and chemotherapy.

09-09-2019 | Small-cell lung cancer | News | Article

CASPIAN: Durvalumab addition boosts SCLC survival

Adding durvalumab to first-line chemotherapy significantly improves the overall survival of patients with extensive-stage small-cell lung cancer, a phase III trial shows.

Image Credits